ST-segment elevation myocardial infarction.

ST-segment elevation myocardial infarction (STEMI) is the most acute manifestation of coronary artery disease and is associated with great morbidity and mortality. A complete thrombotic occlusion developing from an atherosclerotic plaque in an epicardial coronary vessel is the cause of STEMI in the majority of cases. Early diagnosis and immediate reperfusion are the most effective ways to limit myocardial ischaemia and infarct size and thereby reduce the risk of post-STEMI complications and heart failure. Primary percutaneous coronary intervention (PCI) has become the preferred reperfusion strategy in patients with STEMI; if PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolysis therapy should be administered to dissolve the occluding thrombus. The initiation of networks to provide around-the-clock cardiac catheterization availability and the generation of standard operating procedures within hospital systems have helped to reduce the time to reperfusion therapy. Together with new advances in antithrombotic therapy and preventive measures, these developments have resulted in a decrease in mortality from STEMI. However, a substantial amount of patients still experience recurrent cardiovascular events after STEMI. New insights have been gained regarding the pathophysiology of STEMI and feed into the development of new treatment strategies.

Citation

Birgit Vogel, Bimmer E Claessen, Suzanne V Arnold, Danny Chan, David J Cohen, Evangelos Giannitsis, C Michael Gibson, Shinya Goto, Hugo A Katus, Mathieu Kerneis, Takeshi Kimura, Vijay Kunadian, Duane S Pinto, Hiroki Shiomi, John A Spertus, P Gabriel Steg, Roxana Mehran. ST-segment elevation myocardial infarction. Nature reviews. Disease primers. 2019 Jun 06;5(1):39

Mesh Tags

Substances

PMID: 31171787

search → result